Adaptive Biotechnologies exec sells 19,037 shares
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an option exercise and related share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an option exercise and related share sale. On April 27, 2026, she completed an open-market sale of 19,037 shares of common stock at a weighted average price of $14.23 per share.
That same day, she exercised stock options to acquire 14,707 shares of common stock at an exercise price of $8.46 per share from a grant vesting over four years and expiring in 2033. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
19,037 shs ($271K)
Approx. gross sale proceeds
$271K
Approx. exercise cost
$124K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,707 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,707 | $8.46 | $124K |
| Sale | Common Stock | 19,037 | $14.23 | $271K |
Holdings After Transaction:
Stock Option (right to buy) — 45,731 contracts (Direct);
Common Stock — 377,802 shares (Direct)
Footnotes (3)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares sold: 19,037 shares
Sale price: $14.23 per share
Options exercised: 14,707 shares
+2 more
5 metrics
Shares sold
19,037 shares
Common stock sold in open-market transaction on April 27, 2026
Sale price
$14.23 per share
Weighted average sale price; trades ranged from $14.08 to $14.34
Options exercised
14,707 shares
Common stock acquired via option exercise on April 27, 2026
Option exercise price
$8.46 per share
Exercise price for stock options converted into common shares
Remaining options
45,731 options
Stock Option (right to buy) position after transactions; expires March 6, 2033
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
vesting financial
"The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider stock transactions did Julie Rubinstein report at Adaptive Biotechnologies (ADPT)?
Julie Rubinstein reported both an option exercise and a share sale. She exercised options for 14,707 shares of common stock and sold 19,037 shares in an open-market transaction, all dated April 27, 2026, according to the Form 4 filing.
What stock options did Julie Rubinstein exercise in this Adaptive Biotechnologies (ADPT) Form 4?
She exercised options covering 14,707 shares of common stock. These options had an exercise price of $8.46 per share, vested over four years starting March 4, 2024, and are part of a grant scheduled to expire on March 6, 2033.
Were Julie Rubinstein’s ADPT trades made under a Rule 10b5-1 trading plan?
Yes. The filing states the transactions were made under a Rule 10b5-1 plan. A footnote explains they were effected pursuant to a trading plan adopted on November 18, 2025, indicating the timing of these trades was pre-arranged rather than decided spontaneously.
What vesting terms apply to the Adaptive Biotechnologies stock options exercised by Julie Rubinstein?
The options vest over four years with monthly installments. One quarter of the shares vested on March 4, 2024, and one forty-eighth of the shares vests at the end of each full month of continuous service thereafter until the grant is fully vested.
How many Adaptive Biotechnologies stock options remain from this grant after the reported exercise?
The filing shows 45,731 stock options remaining from this grant. These are described as “Stock Option (right to buy)” with an exercise price of $8.46 per share and an expiration date of March 6, 2033, following the 14,707-share exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
